Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
January 23 2018 - 04:01PM
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced the
closing of its previously announced underwritten public offering of
common stock, including the exercise in full by the underwriters of
their option to purchase an additional 1,063,433 shares at the
public offering price of $67.00 per share. The exercise of the
option to purchase additional shares brought the total number of
shares of common stock sold by Agios to 8,152,986 shares and
increased the amount of gross proceeds raised in the offering,
before underwriting discounts and estimated expenses of the
offering, to approximately $546.3 million.
J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and
Cowen and Company, LLC acted as joint book-running managers for the
offering. RBC Capital Markets, LLC and SunTrust Robinson Humphrey,
Inc. served as lead managers for the offering.
The shares were offered by Agios pursuant to an automatically
effective shelf registration statement that was previously filed
with the Securities and Exchange Commission (“SEC”). A prospectus
supplement relating to, and describing the terms of, the offering
has been filed with the SEC and is available on the SEC’s web site
at www.sec.gov. Copies of the prospectus supplement and the
accompanying prospectus relating to this offering can be obtained
from J.P. Morgan Securities LLC, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, New York 11717,
telephone: 866-803-9204; Goldman Sachs & Co. LLC, Attn:
Prospectus Department, 200 West Street, New York, New York 10282,
telephone: 866-471-2526, facsimile: 212-902-9316, e-mail:
prospectus-ny@ny.email.gs.com; or Cowen and Company, LLC, c/o
Broadridge Financial Services, 1155 Long Island Avenue, Edgewood,
NY 11717, Attention: Prospectus Department, or by telephone at
(631) 274-2806.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Agios Pharmaceuticals, Inc.
Agios is focused on discovering and developing novel
investigational medicines to treat cancer and rare genetic diseases
through scientific leadership in the field of cellular metabolism.
In addition to an active research and discovery pipeline across
both therapeutic areas, Agios has an approved oncology precision
medicine and multiple first-in-class investigational therapies in
clinical and/or preclinical development. All Agios programs focus
on genetically identified patient populations, leveraging our
knowledge of metabolism, biology and genomics.
Cautionary Note Regarding Forward Looking
Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. The words “anticipate,” “believe,” “estimate,” “expect,”
“intend,” “may,” “plan,” “predict,” “project,” “would,” “could,”
“potential,” “possible,” “hope” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Actual
results may differ materially from those projected or implied in
these forward-looking statements. Factors that may cause such a
difference include, without limitation, risks and uncertainties
related to the impact of general economic, industry or political
conditions in the United States or internationally. You should not
place undue reliance on these forward-looking statements.
Additional risks and uncertainties relating to the offering, Agios
and its business can be found under the caption “Risk Factors”
included in Agios’ Quarterly Report on Form 10-Q for the quarter
ended September 30, 2017, Agios’ prospectus supplement filed with
the SEC on January 19, 2018, and other filings that Agios may make
with the SEC in the future. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and Agios expressly disclaims any obligation to update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
CONTACTS:Kendra Adams, Senior Director,
Investor & Public Relations Kendra.Adams@agios.com
617-844-6407
Renee Leck, Senior Manager, Investor & Public
RelationsRenee.Leck@agios.com617-649-8299
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Mar 2023 to Mar 2024